Jang Youn-Jae, Kim Hye-Yoom, Na Se-Won, Hong Mi-Hyeon, Yoon Jung-Joo, Lee Ho-Sub, Kang Dae-Gill
Hanbang Cardio-Renal Syndrome Research Center, Wonkwang University, Iksan 54538, Republic of Korea.
College of Oriental Medicine, Professional Graduate School of Oriental Medicine, Wonkwang University, Iksan 54538, Republic of Korea.
Pharmaceuticals (Basel). 2024 Aug 27;17(9):1132. doi: 10.3390/ph17091132.
Myocardial infarction (MI) is a leading cause of heart failure, characterized by adverse cardiac remodeling. This study evaluated the cardioprotective potential of Dohongsamul-tang (DHT), a traditional Korean herbal formula, in a rat model of MI-induced heart failure. Rats underwent left anterior descending (LAD) artery ligation and were treated with either 100 mg/kg or 200 mg/kg of DHT daily for 8 weeks. DHT treatment significantly improved cardiac function, as evidenced by increased ejection fraction (EF) from 62.1% to 70.1% (100 mg/kg) and fractional shortening (FS) from 32.3% to 39.4% (200 mg/kg) compared to the MI control group. Additionally, DHT reduced infarct size by approximately 63.3% (from 60.0% to 22.0%) and heart weight by approximately 16.7% (from 3.6 mg/g to 3.0 mg/g), and significantly decreased levels of heart failure biomarkers: LDH was reduced by 37.6% (from 1409.1 U/L to 879.1 U/L) and CK-MB by 47.6% (from 367.3 U/L to 192.5 U/L). Histological analysis revealed a reduction in left ventricle (LV) fibrosis by approximately 50% (from 24.0% to 12.0%). At the molecular level, DHT inhibited the expression of phospho-JAK by 75% (from 2-fold to 0.5-fold), phospho-STAT3 by 30.8% (from 1.3-fold to 0.9-fold), Bax/Bcl-2 by 56.3% (from 3.2-fold to 1.4-fold), and caspase-3 by 46.3% (from 1.23-fold to 0.66-fold). These results suggest that DHT exerts cardioprotective effects by modulating the JAK/STAT3 signaling pathway, highlighting its potential as a therapeutic option for heart failure.
心肌梗死(MI)是心力衰竭的主要原因,其特征是心脏发生不良重塑。本研究评估了韩国传统草药配方多红四味汤(DHT)在心肌梗死诱导的心力衰竭大鼠模型中的心脏保护潜力。大鼠接受左冠状动脉前降支(LAD)结扎,并每天给予100mg/kg或200mg/kg的DHT,持续8周。与心肌梗死对照组相比,DHT治疗显著改善了心脏功能,表现为射血分数(EF)从62.1%增加到70.1%(100mg/kg组),缩短分数(FS)从32.3%增加到39.4%(200mg/kg组)。此外,DHT使梗死面积减少了约63.3%(从60.0%降至22.0%),心脏重量减少了约16.7%(从3.6mg/g降至3.0mg/g),并显著降低了心力衰竭生物标志物的水平:乳酸脱氢酶(LDH)降低了37.6%(从1409.1U/L降至879.1U/L),肌酸激酶同工酶(CK-MB)降低了47.6%(从367.3U/L降至192.5U/L)。组织学分析显示左心室(LV)纤维化减少了约50%(从24.0%降至12.0%)。在分子水平上,DHT抑制磷酸化JAK的表达达75%(从2倍降至0.5倍),磷酸化STAT3的表达达30.8%(从1.3倍降至0.9倍),Bax/Bcl-2的表达达56.3%(从3.2倍降至1.4倍),半胱天冬酶-3的表达达46.3%(从1.23倍降至0.66倍)。这些结果表明,DHT通过调节JAK/STAT3信号通路发挥心脏保护作用,突出了其作为心力衰竭治疗选择的潜力。